Indian Healtcare firm gets USFDA nod for Symmetrel’s generic version – Feedback

Drug firm Jubilant Life SciencesBSE -2.21 % today said its subsidiary has received final approval from the US health regulator for Amantadine Hydrochloride tablets, an anti-viral and anti-Parkinsons drug.

Approved drug, generic version of Symmetrel of Endo, is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. It is also indicated in the treatment of Parkinsonism and drug-induced extrapyramidal reactions. “Jubilant Pharma Ltd, a material wholly owned subsidiary of the company, through one of its wholly owned subsidiaries, has received abbreviated new drug application (ANDA) final approval for Amantadine Hydrochloride tablets, 100 mg,”.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/jubilant-pharma-gets-usfda-nod-for-symmetrels-generic-version/articleshow/62848076.cms

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *